NCT00246272View on ClinicalTrials.gov

An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

PHASE3CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

October 31, 2004

Study Completion Date

May 31, 2006

Conditions
Schizophrenia
Interventions
DRUG

risperidone

All Listed Sponsors
lead

Janssen-Ortho Inc., Canada

INDUSTRY

NCT00246272 - An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone | Biotech Hunter | Biotech Hunter